株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

感染症診断の世界市場 - 成長、動向、予測(2020年~2025年)

Infectious Disease Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 921848
出版日 ページ情報 英文 112 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.80円で換算しております。
Back to Top
感染症診断の世界市場 - 成長、動向、予測(2020年~2025年) Infectious Disease Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 112 Pages
担当者のコメント
下記の日本語概要は、最新版レポートの内容と異なる場合があります。詳細はお問合せください。
概要

感染症は、死因の主な原因の1つです。病原体が変化し、新型疾患が発生する中、医師が治療法を決定するために、適切な診断技術を選択する必要性があります。技術進歩により、感染症診断を取り巻く状況は急速な変容を遂げています。質量分析や次世代シーケンス(NGS)などの新技術や研究開発活動は、迅速診断のあり様を変えています。さらに、エンドユーザーのPOC検査に対する選好の高まりも、産業の成長を促進すると予想されます。また、様々な主要企業が、開発途上国向けのPOC診断ソリューションの開発に注力しています。

当レポートでは、世界の感染症診断市場を調査し、市場の概要、用途・製品・技術・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会および将来動向、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場の成長要因
    • 感染症の有病率の世界的な増加
    • 集中型ラボから分散型POC検査への焦点のシフト
    • 感染症診断に関する研究
  • 市場の阻害要因
    • 不十分な払い戻し制度
    • 新しい診断技術の使用を制限する医療費の上昇
  • ファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入企業の脅威
    • 代替製品・サービスの脅威
    • 競合度合い

第5章 市場セグメンテーション

  • 用途別
    • 肝炎
    • ヒト免疫不全ウイルス(HIV)
    • クラミジアトコチマス(CT) & 淋病(NG)
    • 院内感染
    • ヒトパピローマウイルス(HPV)
    • 結核(TB)
    • インフルエンザ
    • その他
  • 製品別
    • アッセイ・キット・試薬
    • 装置
    • サービス・ソフトウェア
  • 技術別
    • ポリメラーゼ連鎖反応(PCR)
    • 等温核酸増幅テクノロジー(INAAT)
    • 免疫診断
    • DNAマイクロアレイ
    • 臨床微生物学
    • DNAシーケンス・次世代シーケンス(NGS)
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Biomerieux SA
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories
    • Danaher Corporation
    • F. Hoffmann-La Roche AG
    • Siemens AG
    • Thermo Fisher Scientific
    • Quidel Corporation
    • Luminex

第7章 市場機会および将来動向

目次
Product Code: 67137

Market Overview

Infectious diseases are one of the leading causes of morbidity and mortality across the globe. Diagnostics is the primary step for disease discovery and treatment leading to the eradication of infectious diseases. Owing to ever-evolving pathogens and emerging new diseases, there is dire need to identify suitable diagnostics technique that can help physicians to decide the appropriate treatment. This can also help to control the outbreak of the disease in the population. Technological advancement has rapidly changed the landscape of infectious disease diagnostics. Scientific research and development activities in novel technologies and techniques such as mass spectrometry and next-generation sequencing (NGS) are changing the way how rapid diagnostics are being performed to detect diseases. In addition, the growing inclination of end-user towards point-of-care testing is also anticipated to drive industry growth. The point-of-care diagnostics provide rapid actionable information for patients' care at the real-time and site of an encounter with the healthcare system. Additionally, various major players are focused on research and development activities to develop point-of-care diagnostics solutions for developing countries.

Scope of the Report

As per the scope of the report infectious disease diagnostics involves identifying the presence of foreign antigen/organism using diagnostic tools such as kits and/or devices. In the report, a detailed analysis of the Infectious disease diagnostics market is provided. The market is evaluated by collating revenues generated across segments, categorized by product, technology, application, and geography.

Key Market Trends

Viral Infection diagnostics are expected to cover a large share of the market

A viral infection is one of the major public health concerns around the world. As per a report by Meryem Jefferies et al. published in the World Journal of Clinical Cases 2018, every year 1.4 million people die from viral hepatitis-related cirrhosis and liver cancer. Furthermore, according to the World Health Organization, 37.9 million people were living with HIV/AIDS worldwide in 2018. Moreover, an estimated 32 million people have died of HIV.

Thus, owing to the high prevalence of these dreadful illnesses, the demand for early diagnostic tests is expected to increase as early diagnosis may reduce the spread of the disease. Hence, this market is expected to increase in the future.

North America is expected to Hold Largest Market Share

According to Charbel el Bcheraoui et al. published in the Journal of the American Medical Association 2018, between 1980 and 2014, there were more than 4 million deaths due to infectious diseases recorded in the United States. In 2014, a total of more than 110,000 deaths (a rate of 34.10 deaths per 100*000 persons) were due to infectious diseases in the United States compared to a total of approximately 72,000 deaths (a rate of 41.95 deaths per 100*000 persons) in 1980.

As the United States is a developed economy, it has a well-structured healthcare system. This has helped the country with better access to the diagnostic tests that are available in the market. Diagnostic tests help early diagnosis of a disease that can help the spread of these infectious diseases. As a result, this can be noticed in the decreasing rate of infectious diseases over the years. However, the rate still remains high, which is expected to help the growth of this market

Competitive Landscape

The majority of the Infectious disease diagnostics are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market growth.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Global Prevalence of Infectious Diseases
    • 4.2.2 Shift in Focus From Centralized Laboratories to Decentralized Point-Of-Care Testing
    • 4.2.3 Research on Infectious Disease Diagnostics
  • 4.3 Market Restraints
    • 4.3.1 Inadequate Reimbursements
    • 4.3.2 Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Hepatitis
    • 5.1.2 Human Immunodeficiency Virus (HIV)
    • 5.1.3 Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
    • 5.1.4 Hospital-Acquired Infections
    • 5.1.5 Human Papillomavirus (HPV)
    • 5.1.6 Tuberculosis (TB)
    • 5.1.7 Influenza
    • 5.1.8 Other Infectious Diseases
  • 5.2 By Product
    • 5.2.1 Assays, Kits, & Reagents
    • 5.2.2 Instruments
    • 5.2.3 Services & Software
  • 5.3 By Technology
    • 5.3.1 Polymerase Chain Reaction (PCR)
    • 5.3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
    • 5.3.3 Immunodiagnostics
    • 5.3.4 DNA Microarray
    • 5.3.5 Clinical Microbiology
    • 5.3.6 DNA Sequencing & Next-Generation Sequencing (NGS)
    • 5.3.7 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biomerieux SA
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Becton, Dickinson and Company
    • 6.1.4 Bio-Rad Laboratories
    • 6.1.5 Danaher Corporation
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Siemens AG
    • 6.1.8 Thermo Fisher Scientific
    • 6.1.9 Quidel Corporation
    • 6.1.10 Luminex

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top